Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02640209 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT02640209: Clinical Trial Early Phase 1 study, sponsored by University of Pennsylvania.
NCT02640209 is a Early Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02640209, a Early Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Open-label pilot study to determine safety and efficacy of CART-19 cells in combination with ibrutinib. The target dose will be 1-5x10xE8 CART-19 transduced cells administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3. 15 evaluable subjects (adults) with relapsed or refractory CLL/SLL who have achieved partial response or stable disease on ibrutinib therapy will be eligible to receive CART-19 therapy.
Interventions
- BIOLOGICAL CART 19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-01-29 |
| Est. Completion | 2019-07-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02640209
The ClinicalTrials.gov registry entry for NCT02640209 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CART 19 is the first listed.
NCT02640209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02640209 about?
NCT02640209 is a clinical study titled "Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)". Open-label pilot study to determine safety and efficacy of CART-19 cells in combination with ibrutinib. The target dose will be 1-5x10xE8 CART-19 transduced cells administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3. 15 evaluable subjects (adults) with relapsed or refractory CLL/S...
What is the current status of trial NCT02640209?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2016-01-29. Estimated completion is 2019-07-16.
What interventions are being tested in trial NCT02640209?
The interventions under investigation include: CART 19 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02640209?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.